passages.id: split_1_test_2274_passage
passages.type: progene_text
passages.text: In November 1997 , the FDA cleared oprelvekin for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in susceptible patients with non - myeloid malignancies 12703021 .